Video wird geladen...

Video konnte nicht geladen werden

Zur Startseite

The peptide hypocrisy ‘Health’ commerce in full effect Eli Lilly sources some API, active pharmaceutical ingredient From China while lobbying against compounders using Chinese sourced ingredients Then committed $7 billion to acquire a Chinese peptide company JRE #2469

61,157 Aufrufe • vor 3 Monaten •via X (Twitter)

0 Kommentare

Keine Kommentare verfügbar

Kommentare vom Original-Post werden hier angezeigt

Ähnliche Videos

Swedish Prime Minister Ulf Kristersson said China often has access to the European market in ways that European companies do not enjoy with the same ease in China. He said Europe cannot allow China to have one set of rules while European companies operate under a completely different set of rules. That is the punchline. For years, Europe has restricted or excluded Chinese companies under the language of “security.” Huawei. ZTE. Chinese telecom firms. Chinese solar products. Chinese EVs. Chinese batteries. Chinese infrastructure. Whenever Chinese companies become too competitive, Europe suddenly discovers “risk,” “dependency,” “distortion,” or “strategic vulnerability.” But when China responds with its own controls, tariffs, rare earth restrictions, or market measures, Europe starts crying about fairness. Classic. China has not banned European industrial giants from the Chinese market the way Europe has tried to politically suffocate Chinese companies. Volkswagen, BMW, Mercedes, Airbus, Siemens, BASF, Schneider, LVMH, and countless European firms have made fortunes in China for decades. China opened its market, built supply chains, created demand, and let European companies profit massively. Europe took the money. Then it blocked Chinese firms, joined U.S. containment, restricted high-end exports, attacked Chinese clean-tech industries, and now complains that China enjoys unfair access. If Europe really wants “one set of rules,” it should be careful what it asks for. Because China can play that game too. The difference is simple: Europe complains about access while using access as a weapon. China has shown restraint. Perhaps too much restraint. If Beijing treated European companies the way Europe treats Chinese companies, Brussels would discover very quickly what “same rules” actually means.

𝘊𝘰𝘳𝘳𝘪𝘯𝘦

27,639 Aufrufe • vor 24 Tagen

The leaders of Sinopep, a Chinese drug company (controlled by the CCP) that the FDA has shockingly allowed to supply ingredients for America's popular weight-loss drugs (like those in Ozempic and Wegovy), have strong ties to Chinese government spy and military programs. The chairman, Tong Ziquan (a Singapore citizen), is part of China's special "High-End Foreign Experts Plan" and "National Major Talent Projects". These replaced the famous "Thousand Talents Program," which the FBI says helps China steal U.S. tech and secrets. A 2019 U.S. Senate report called these programs tools to hurt America's tech edge. The senior VP of Sinopep, Shi Guoqiang (also known as George Shi, a U.S. citizen), used to work at Scripps Research and Merck. He's in China's "Hundred Talents Plan" from the Chinese Academy of Sciences. The FBI warns these plans recruit experts, do background checks on them and provide them with intelligence, train them, and pay them to bring knowledge back to China, essentially making the participants in these programs employees of the Chinese government. The company Co-founder Hong Yu is a professor at Zhejiang University, which runs secret defense labs for China's army (the PLA). Just in 2025, the province gave about $5.6 million to the PLA for military work. This is the team running a company the U.S. FDA Dr. Marty Makary has cleared to import ingredients used in popular weight loss GLP-1 medications, giving the CCP access to America’s pharmaceutical supply chain. Did anyone bother to vet Sinopep’s China ties before letting this happen? Who's in charge of keeping CCP-linked companies out of the US drug supply? Secretary Kennedy, did you know about Sinopep's links to these Chinese programs (flagged by the FBI and Senate as spy risks) when the FDA gave them the green light?

Laura Loomer

556,109 Aufrufe • vor 3 Monaten